monoclonal antibody "LEQEMBI ®" (lecanemab) for the treatment of early Alzheimer's disease (AD)*. Eisai logo (PRNewsfoto/Eisai Inc.) ...

LEQEMBI selectively binds to soluble Aβ aggregates ... including the establishment of a Patient Assistance Program, to deliver lecanemab to patients awaiting the treatment, aiming to make ...

monoclonal antibody "LEQEMBI®" (lecanemab) for the treatment of early Alzheimer's disease (AD)*. LEQEMBI selectively binds to soluble Aß aggregates (protofibrils**), as well as insoluble Aß ...

Viehbacher, "Biogen") announced today that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aß) ...

monoclonal antibody "LEQEMBI ®" (lecanemab) for the treatment of early Alzheimer's disease (AD)*. LEQEMBI's approval is based on the large global Phase 3 Clarity AD study. In the Clarity AD study ...

LEQEMBI received the Ministry of Food and Drug ... including the establishment of a Patient Assistance Program, to deliver lecanemab to patients awaiting the treatment, aiming to make an impact ...

LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils ... including the establishment of a Patient Assistance Program, to deliver lecanemab to patients awaiting the treatment, aiming to ...